COPENHAGEN, June 8 (Reuters) – Zealand Pharma’s shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments.
(Reporting by Stine Jacobsen and Bhanvi Satija, editing by Anna Ringstrom )
Comments